CN116059203A - 自分泌运动因子抑制剂及其用途 - Google Patents

自分泌运动因子抑制剂及其用途 Download PDF

Info

Publication number
CN116059203A
CN116059203A CN202211516732.7A CN202211516732A CN116059203A CN 116059203 A CN116059203 A CN 116059203A CN 202211516732 A CN202211516732 A CN 202211516732A CN 116059203 A CN116059203 A CN 116059203A
Authority
CN
China
Prior art keywords
cancer
disease
autotaxin inhibitor
compound
autotaxin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202211516732.7A
Other languages
English (en)
Chinese (zh)
Inventor
格雷琴·贝恩
吉莉安·弗朗西斯·埃文斯
约翰·霍华德·哈钦森
戴维·罗纳根
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cybertherapy Co ltd
Original Assignee
Cybertherapy Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cybertherapy Co ltd filed Critical Cybertherapy Co ltd
Publication of CN116059203A publication Critical patent/CN116059203A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Reproductive Health (AREA)
CN202211516732.7A 2015-05-27 2016-05-24 自分泌运动因子抑制剂及其用途 Pending CN116059203A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562167216P 2015-05-27 2015-05-27
US62/167,216 2015-05-27
CN201680044106.9A CN107921048A (zh) 2015-05-27 2016-05-24 自分泌运动因子抑制剂及其用途
PCT/US2016/033933 WO2016191427A1 (en) 2015-05-27 2016-05-24 Autotaxin inhibitors and uses thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201680044106.9A Division CN107921048A (zh) 2015-05-27 2016-05-24 自分泌运动因子抑制剂及其用途

Publications (1)

Publication Number Publication Date
CN116059203A true CN116059203A (zh) 2023-05-05

Family

ID=57393709

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202211516732.7A Pending CN116059203A (zh) 2015-05-27 2016-05-24 自分泌运动因子抑制剂及其用途
CN201680044106.9A Pending CN107921048A (zh) 2015-05-27 2016-05-24 自分泌运动因子抑制剂及其用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201680044106.9A Pending CN107921048A (zh) 2015-05-27 2016-05-24 自分泌运动因子抑制剂及其用途

Country Status (14)

Country Link
US (2) US10632104B2 (enExample)
EP (2) EP4026549A1 (enExample)
JP (2) JP6873919B2 (enExample)
KR (2) KR102663569B1 (enExample)
CN (2) CN116059203A (enExample)
AU (4) AU2016268250B2 (enExample)
BR (1) BR122023011445B1 (enExample)
CA (1) CA2986759C (enExample)
EA (2) EA036337B1 (enExample)
ES (1) ES2915267T3 (enExample)
IL (2) IL280863B2 (enExample)
MX (2) MX2017015225A (enExample)
SG (1) SG10201911204WA (enExample)
WO (1) WO2016191427A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20210957T1 (hr) 2013-11-22 2021-09-17 Sabre Therapeutics Llc Spojevi inhibitori autotaksina
EP4026549A1 (en) 2015-05-27 2022-07-13 Sabre Therapeutics LLC Autotaxin inhibitors and uses thereof
CN107021915A (zh) * 2017-04-27 2017-08-08 李亚庆 一种治疗妇科炎症的化合物及制备方法和应用
EP3668993A4 (en) * 2017-08-14 2021-05-12 Camp4 Therapeutics Corporation HEPATIC DISEASE TREATMENT METHODS
WO2019172651A1 (ko) 2018-03-06 2019-09-12 주식회사 엘지화학 편광판 및 이를 포함하는 화상 표시 장치
CA3112414A1 (en) * 2018-09-18 2020-03-26 Metacrine, Inc. Farnesoid x receptor agonists for the treatment of disease
CN112190708B (zh) * 2019-07-08 2023-09-05 上海交通大学医学院附属瑞金医院 趋化因子受体ccr6抑制剂在预防银屑病复发中的新应用
AU2022421244A1 (en) 2021-12-22 2024-07-11 Camp4 Therapeutics Corporation Modulation of gene transcription using antisense oligonucleotides targeting regulatory rnas
CN114767863B (zh) * 2022-04-29 2024-01-30 西北工业大学 一种enpp2基因或蛋白在调控结直肠癌细胞中的应用
WO2023215196A1 (en) * 2022-05-03 2023-11-09 Sabre Therapeutics Llc Polymorphic and salt forms of the autotaxin inhibitor cudetaxestat
US20250281486A1 (en) * 2022-05-05 2025-09-11 The Trustees Of Indiana University Therapeutic strategies to manage facial contractures post injury
GR1010570B (el) 2022-12-22 2023-11-17 Uni-Pharma Κλεων Τσετης Φαρμακευτικα Εργαστηρια Α.Β.Ε.Ε., 4-(2-(4-((2,4-διοξοθειαζολιδιν-5-υλ)μεθυλ)φαινοξυ) παραγωγα με δραση αναστολης της αυτοταξινης
TW202502735A (zh) * 2023-03-02 2025-01-16 印度商吉德斯生命科學有限公司 新穎atx抑制劑
CN116239577A (zh) * 2023-03-27 2023-06-09 沈阳药科大学 一种制备Cudetaxestat的方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103201262A (zh) * 2010-08-20 2013-07-10 艾米拉医药股份有限公司 自分泌运动因子抑制剂及其用途
WO2015048301A1 (en) * 2013-09-26 2015-04-02 Pharmakea, Inc. Autotaxin inhibitor compounds
WO2015077503A1 (en) * 2013-11-22 2015-05-28 Pharmakea, Inc. Autotaxin inhibitor compounds

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5210574A (en) 1991-03-08 1993-05-11 Mita Industrial Co., Ltd. Photosensitive drum body-mounting mechanism including a drive coupling member with a coupling protrusion adapted to bite into the inner surface of the mechanism's photosensitive drum
US5186522A (en) 1991-09-24 1993-02-16 Midland Brake, Inc. Air dryer purge line
EP0630453B1 (en) 1992-11-10 1998-01-28 Fluid Power Industries, Incorporated Solenoid valve assembly
US5407368A (en) 1992-12-15 1995-04-18 Minnesota Mining And Manufacturing Company Electrode connector
US5761473A (en) 1993-01-08 1998-06-02 International Business Machines Corporation Method and system for increased instruction synchronization efficiency in a superscalar processsor system utilizing partial data dependency interlocking
US5564949A (en) 1995-01-05 1996-10-15 Thomas & Betts Corporation Shielded compact data connector
JP2664048B2 (ja) 1995-03-27 1997-10-15 科学技術庁金属材料技術研究所長 六フッ化二ケイ素の合成法
GB9514473D0 (en) 1995-07-14 1995-09-13 Glaxo Lab Sa Chemical compounds
EP1284728A4 (en) 1999-10-22 2004-05-19 Merck & Co Inc MEDICINES FOR TREATING ADDICTIC ADDICTION
US6890933B1 (en) 2000-02-24 2005-05-10 President And Fellows Of Harvard College Kinesin inhibitors
ATE332903T1 (de) 2000-10-03 2006-08-15 Lilly Icos Llc Kondensierte pyridoindolderivate
AR035857A1 (es) 2001-04-11 2004-07-21 Novirio Pharmaceuticals Ltd Fenilindoles; sus composiciones farmaceuticas y sus usos
IL160752A0 (en) 2001-09-27 2004-08-31 Hoffmann La Roche Indole derivatives as cox ii inhibitors
US7528165B2 (en) 2001-12-13 2009-05-05 National Health Research Institutes Indole compounds
US7393960B2 (en) 2002-08-29 2008-07-01 Merck & Co., Inc. Indoles having anti-diabetic activity
HRP20050181A2 (en) 2002-08-29 2006-03-31 Merck & Co. Inc. Indoles having anti-diabetic activity
BRPI0410454A (pt) 2003-05-19 2006-06-13 Irm Llc composições e compostos imunossupressores
ATE396970T1 (de) 2003-12-23 2008-06-15 Lundbeck & Co As H 2-(1h-indolylsulfanyl)-benzylaminderivate als ssri
WO2005111278A1 (ja) 2004-05-19 2005-11-24 Sumitomo Electric Industries, Ltd. Ｉｉｉ族窒化物半導体結晶およびその製造方法ならびにｉｉｉ族窒化物半導体デバイス
KR101141650B1 (ko) 2004-09-30 2012-05-17 엘지전자 주식회사 매체접속제어 계층에서의 데이터 처리 방법 및 이동통신용단말
WO2006041961A1 (en) 2004-10-05 2006-04-20 GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTHAND HUMAN SERVICES Arylthioindole tubulin polymerization inhibitors and methods of treating or preventing cancer using same
WO2007134169A2 (en) 2006-05-10 2007-11-22 Nuada, Llc Indole, benzimidazole, and benzolactam boronic acid compounds, analogs thereof and methods of use thereof
WO2006050236A2 (en) 2004-11-01 2006-05-11 Nuada, Llc Compounds and methods of use thereof
US20060270634A1 (en) 2005-05-06 2006-11-30 Miller Duane D Acetal phosphate-derived LPA mimics, PPARgamma activators, and autotaxin inhibitors
AR054394A1 (es) 2005-06-17 2007-06-20 Lundbeck & Co As H Derivados de 2- (1h-indolilsulfanil)-aril amina
WO2007041600A2 (en) 2005-10-03 2007-04-12 Luminescent Technologies, Inc. Mask-pattern determination using topology types
ATE526318T1 (de) 2005-12-19 2011-10-15 Glaxosmithkline Llc Farnesoid-x-rezeptor-agonisten
CA2690762C (en) 2007-06-15 2016-06-14 Glenn Prestwich .alpha.-chloro and .alpha.-bromo phosphonate analogs of lysophosphatidic acid and methods of making and using thereof
DE102007047735A1 (de) 2007-10-05 2009-04-09 Merck Patent Gmbh Thiazolderivate
DE102007047738A1 (de) 2007-10-05 2009-04-09 Merck Patent Gmbh Imidazolderivate
DE102007047737A1 (de) 2007-10-05 2009-04-30 Merck Patent Gmbh Piperidin- und Piperazinderivate
US8268891B1 (en) 2007-11-13 2012-09-18 University Of Memphis Research Foundation Autotaxin inhibitors
US8378100B2 (en) 2008-01-09 2013-02-19 University Of Virginia Patent Foundation Phosphonate derivatives as autotaxin inhibitors
US20110110886A1 (en) 2008-06-13 2011-05-12 Yale University Small molecule inhibitors of autotaxin and methods of use
WO2010040080A1 (en) 2008-10-03 2010-04-08 Abby Louise Parrill-Baker Mechanism-based inactivators of autotaxin
DE102008059578A1 (de) 2008-11-28 2010-06-10 Merck Patent Gmbh Benzo-Naphtyridin Verbindungen
CA2745041C (en) 2008-12-01 2017-08-22 Kai Schiemann 2, 5-diamino-substituted pyrido [4, 3-d] pyrimidines as autotaxin inhibitors against cancer
KR20120027177A (ko) * 2009-04-02 2012-03-21 메르크 파텐트 게엠베하 오토탁신 저해제로서의 피페리딘 및 피라진 유도체
AU2010230646B2 (en) 2009-04-02 2015-11-26 Merck Patent Gmbh Heterocyclic compounds as autotaxin inhibitors
EA201101396A1 (ru) 2009-04-02 2012-09-28 Мерк Патент Гмбх Ингибиторы аутотаксина
US8445200B2 (en) 2009-04-15 2013-05-21 The Regents Of The University Of California Genotoxicity as a biomarker for inflammation
US20110020312A1 (en) 2009-05-11 2011-01-27 Niven Rajin Narain Methods for treatment of metabolic disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencers
JP2010267037A (ja) 2009-05-14 2010-11-25 Fujitsu Ltd ディスクアレイ装置
JP2012527444A (ja) 2009-05-20 2012-11-08 イーティーエイチ チューリッヒ 代謝障害に関するターゲッティングマイクロｒｎａ
WO2011002918A1 (en) 2009-06-30 2011-01-06 The University Of Memphis Research Foundation Novel diverse lead compound autotaxin inhibitors
DE102009033392A1 (de) 2009-07-16 2011-01-20 Merck Patent Gmbh Heterocyclische Verbindungen als Autotaxin-Inhibitoren II
DE102009049211A1 (de) 2009-10-13 2011-04-28 Merck Patent Gmbh Sulfoxide
WO2011049433A1 (en) * 2009-10-23 2011-04-28 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Diagnosis and treatment of pruritis
WO2011053597A1 (en) 2009-10-26 2011-05-05 The University Of Memphis Research Foundation Pipemidic acid derivative autotaxin inhibitors
US8497371B2 (en) 2009-10-26 2013-07-30 University Of Memphis Research Foundation Pipemidic acid derivative autotaxin inhibitors
WO2011103430A1 (en) 2010-02-19 2011-08-25 Medivation Technologies, Inc. Pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use
AU2011232058B2 (en) 2010-03-26 2016-09-08 Merck Patent Gmbh Benzonaphthyridinamines as autotaxin inhibitors
WO2011130729A2 (en) 2010-04-16 2011-10-20 Salk Institute For Biological Studies Methods for treating metabolic disorders using fgf
US8771696B2 (en) 2010-11-23 2014-07-08 Regeneron Pharmaceuticals, Inc. Method of reducing the severity of stress hyperglycemia with human antibodies to the glucagon receptor
WO2012100018A1 (en) 2011-01-20 2012-07-26 University Of Tennessee Research Foundation Inhibitors of autotaxin
US9035056B2 (en) 2011-02-18 2015-05-19 Medivation Technologies, Inc. Pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use
AU2012219251B2 (en) 2011-02-18 2016-05-12 Medivation Technologies, Inc. Compounds and methods for treatment of hypertension
CN103533934B (zh) * 2011-03-17 2016-03-30 特尔汗什莫尔医学基础设施研究和服务公司 用于治疗自身免疫性疾病的喹诺酮类似物
WO2012166415A1 (en) 2011-05-27 2012-12-06 Amira Pharmaceuticals, Inc. Heterocyclic autotaxin inhibitors and uses thereof
GB2494154B (en) 2011-08-31 2017-11-29 Metaswitch Networks Ltd Conditional telecommunications
KR20130029948A (ko) 2011-09-16 2013-03-26 현대중공업 주식회사 용접 캐리지 이동용 가이드레일
WO2013054185A1 (en) 2011-10-13 2013-04-18 Pfizer, Inc. Pyrimidine and pyridine derivatives useful in therapy
ES2748656T3 (es) 2011-10-28 2020-03-17 Inhibitaxin Ltd Derivados de piridazina útiles en terapia
JP2013129632A (ja) 2011-12-22 2013-07-04 Ono Pharmaceut Co Ltd Ｅｎｐｐ２阻害化合物
US20130270634A1 (en) 2012-04-12 2013-10-17 Richtek Technology Corporation High voltage device and manufacturing method thereof
TWI633087B (zh) 2012-06-13 2018-08-21 赫孚孟拉羅股份公司 新穎二氮雜螺環烷及氮雜螺環烷
WO2014031170A1 (en) 2012-08-22 2014-02-27 Medivation Technologies, Inc. Pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use
HRP20191937T1 (hr) 2012-09-25 2020-01-10 F. Hoffmann - La Roche Ag Derivati heksahidropirolo [3,4-c]pirola i srodni spojevi kao inhibitori autotaksina (atx) i kao inhibitori proizvodnje lizofosfatidne kiseline (lpa) za liječenje npr. bubrežnih bolesti
BR112015014372A8 (pt) 2012-12-19 2019-10-29 Novartis Ag inibidores de autotaxina, seus usos, e composição e combinação farmacêuticas".
US9409895B2 (en) 2012-12-19 2016-08-09 Novartis Ag Autotaxin inhibitors
TWI499591B (zh) 2013-01-11 2015-09-11 Lilly Co Eli 雙環嘧啶化合物
US9951026B2 (en) 2013-09-17 2018-04-24 Pharmakea, Inc. Heterocyclic vinyl autotaxin inhibitor compounds
WO2015042053A1 (en) 2013-09-17 2015-03-26 Pharmakea, Inc. Vinyl autotaxin inhibitor compounds
AP2016009182A0 (en) 2013-11-05 2016-04-30 Bayer Cropscience Ag Substituted benzamides for treating arthropodes
PL3071560T3 (pl) 2013-11-22 2018-07-31 Basf Se N-acyloiminowe związki heterocykliczne
US9926318B2 (en) 2013-11-22 2018-03-27 Pharmakea, Inc. Tetracyclic autotaxin inhibitors
CL2016001118A1 (es) 2013-11-22 2016-12-02 Basf Se Compuestos heterocíclicos de n-acilimino
US9051320B1 (en) * 2014-08-18 2015-06-09 Pharmakea, Inc. Methods for the treatment of metabolic disorders by a selective small molecule autotaxin inhibitor
EP4026549A1 (en) 2015-05-27 2022-07-13 Sabre Therapeutics LLC Autotaxin inhibitors and uses thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103201262A (zh) * 2010-08-20 2013-07-10 艾米拉医药股份有限公司 自分泌运动因子抑制剂及其用途
WO2015048301A1 (en) * 2013-09-26 2015-04-02 Pharmakea, Inc. Autotaxin inhibitor compounds
WO2015077503A1 (en) * 2013-11-22 2015-05-28 Pharmakea, Inc. Autotaxin inhibitor compounds

Also Published As

Publication number Publication date
EP3302490A1 (en) 2018-04-11
AU2020239656A1 (en) 2020-10-15
EA201792604A1 (ru) 2018-04-30
BR122023011445B1 (pt) 2024-02-27
US10632104B2 (en) 2020-04-28
AU2016268250A1 (en) 2017-12-14
JP2021119158A (ja) 2021-08-12
MX2017015225A (es) 2018-02-19
BR112017025420A2 (pt) 2018-08-07
EA202091731A1 (ru) 2020-11-30
AU2020239656B2 (en) 2022-06-16
KR20180026390A (ko) 2018-03-12
US20200215034A1 (en) 2020-07-09
AU2016268250B2 (en) 2020-08-27
IL280863B1 (en) 2024-03-01
SG10201911204WA (en) 2020-02-27
JP2018515556A (ja) 2018-06-14
KR20240060887A (ko) 2024-05-08
EA039684B1 (ru) 2022-02-28
MX2022007436A (es) 2022-07-19
IL280863B2 (en) 2024-07-01
KR102663569B1 (ko) 2024-05-03
US20180147185A1 (en) 2018-05-31
US12458627B2 (en) 2025-11-04
WO2016191427A1 (en) 2016-12-01
EA036337B1 (ru) 2020-10-28
IL255764A (en) 2018-01-31
ES2915267T3 (es) 2022-06-21
EP3302490B1 (en) 2022-04-13
IL255764B (en) 2021-03-25
CA2986759A1 (en) 2016-12-01
AU2024264577A1 (en) 2024-11-28
EP4026549A1 (en) 2022-07-13
HK1253587A1 (en) 2019-06-21
IL280863A (en) 2021-04-29
JP6873919B2 (ja) 2021-05-19
JP7274521B2 (ja) 2023-05-16
AU2022228098A1 (en) 2022-09-29
EP3302490A4 (en) 2019-01-23
CN107921048A (zh) 2018-04-17
CA2986759C (en) 2025-06-17

Similar Documents

Publication Publication Date Title
JP7274521B2 (ja) オートタキシン阻害剤とその使用
US9951026B2 (en) Heterocyclic vinyl autotaxin inhibitor compounds
US9714240B2 (en) Vinyl autotaxin inhibitor compounds
CA3036062A1 (en) Uses of a lysyl oxidase-like 2 inhibitor
HK40077153A (en) Autotaxin inhibitors and uses thereof
CN104788423B (zh) 一种新的囊性纤维化跨膜传导调节因子抑制剂
WO2016144706A2 (en) Autotaxin inhibitor compounds and uses thereof
BR112017025420B1 (pt) Uso de inibidores de autotaxina
WO2016144704A2 (en) Heterocyclic autotaxin inhibitor compounds
HK1253587B (en) Autotaxin inhibitors and uses thereof
JP2025516335A (ja) オートタキシン阻害剤の多形形態

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination